The Clinic
Studying at IRCM
Core facilities
Bioinformatics and Computational Genomics
Skip navigation links

Research unit director

Time to move forward from "first generation" prognostic gene signatures in early breast cancer. Desmedt C, Michiels S, Haibe-Kains B, Loi S, Sotiriou C, Editorial in Breast Cancer Research and Treatment, 124(2), November 2010.

Classification models for breast cancer molecular subtyping: What is the best candidate for a translation into clinic? Haibe-Kains B, Editorial in Women’s Health, 6(5):623-625, September 2010.

Peer-reviewed publications
DNA methylation profiling reveals a predominant immune component in breast cancers. Dedeurwaerder S, Desmedt C, Calonne E, Singha SK, Haibe-Kains B, Defrance M, Michiels S, Volkmar M, Deplus R, Luciani J, Lallemand F, Larsimont D, Toussaint J, Haussy S, Rothé F, Rouas G, Metzger O, Majjaj S, Saini K, Putmans P, Hames G, Baren NV, Coulie PG, Piccart M, Sotiriou C, Fuks F. EMBO Mol Med. 2011 Sep 12.

survcomp: an R/Bioconductor package for performance assessment and comparison of survival models. Schröder MS, Culhane AC, Quackenbush J, Haibe-Kains B. Bioinformatics. 2011 Sep 7.

Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response. Li Q, Eklund AC, Birkbak NJ, Desmedt C, Haibe-Kains B, Sotiriou C, Symmans WF, Pusztai L, Brunak S, Richardson AL, Szallasi Z. BMC Bioinformatics. 2011 Jul 28;12(1):310.

Global MicroRNA Expression Profiling Identifies MiR-210 Associated with Tumor Proliferation, Invasion and Poor Clinical Outcome in Breast Cancer. Rothé F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, Majjaj S, Badran B, Fayyad-Kazan H, Desmedt C, Harris AL, Piccart M, Sotiriou C. PLoS ONE. 2011;6(6):e20980. Epub 2011 Jun 29.

Minimising Immunohistochemical False Negative ER Classification Using a Complementary 23 Gene Expression Signature of ER Status. Li Q, Eklund AC, Juul N, Haibe-Kains B, Workman CT, Richardson AL, Szallasi Z, and Swanton C in PLoS ONE; 5(12): e15031, 2010.

Low CD10 mRNA expression identifies high-risk ductal carcinoma in situ (DCIS). Toussaint J, Durbecq V, Altintas S, Doriath V, Rouas G, Paesmans M, Bedard P, Haibe-Kains B, Tjalma WA, Larsimont D, Piccart MJ, Sotiriou C in PLoS ONE, 5(8):e12100, 2010.

Long term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Le Calvé B, Rynkowski M, LeMercier M, Bruyère C, Lonez C, Gras T, Haibe-Kains B, Bontempi G, Decaestecker C, Ruysschaert JM, Kiss R and Lefranc F in Neoplasia, 12(9):727-739, 2010.

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor positive breast cancer. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans FW, Bardelli A, Ellis P, Tutt AN, Gillett CE, Mills GB, Hennessy BT, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C in PNAS, 107(22):20208-10213, 2010.

Evaluation of an RNA interference screen-derived mitotic and ceramide pathway meta- gene in paclitaxel-treated primary ER-/PR-/ERBB2- breast cancer: a retrospective analysis of five clinical trials. Juul N, Eklund AC, Li Q, Burrell RA, Gerlinger M, Valero V, Andreopoulou E, Esteva FJ, Symmans FW, Desmedt C, Haibe-Kains B, Sotiriou C, Pusztai L, Szallasi Z and Swanton C in Lancet Oncology, 11(4):358-364, 2010.

A fuzzy gene expression-based computational approach improves breast cancer prognostication. Haibe-Kains B*, Desmedt C*, Rothé F, Sotiriou C and Bontempi G in Genome Biology 11(2):R18, 2010.

Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Li Y, Desmedt C, Sotiriou C, Szallasi Z, Iglehart JD, Richardson AL, Wang ZC in Nature Medecine 16(2):214-218, 2010.

All rights reserved: IRCM 2011_110 avenue des Pins Ouest - Montréal (Québec) H2W 1R7 – Canada